The National Institute for Health and Care Excellence (NICE) TA875, has approved Semaglutide (Wegovy®) for managing overweight and obese patients. This has been widely publicised, however, the current agreement by NICE is that it can only be prescribed by a specialist weight management (tier 3) service (i.e. hospital only).
As advised by the North Central London (NCL) Integrated Care Board: Wegovy® is NOT available to be prescribed from GP Practices for this indication.
There is no commissioned Tier 3 Weight Management Service for NCL (North Central London) patients at the moment, however there is a working group looking into this, and we hope this service will be in place in the next 3-6 months.
Similar medications (Ozempic and Rybelsus) are licensed for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise, this will only be prescribed in line with our current diabetes pathways.
If you would like to consider other weight management options, please book an appointment with a health care assistant to discuss what is available to you.